Fig. 4

Change from baseline to Month 6 in HFEM patients receiving galcanezumab who 1) did not shift, 2) shifted to LFEM or 3) VLFEM for ≥ 3 consecutive months until the end of the study for (a) migraine headache days/month, (b) MSQ-RFR score and (c) MIDAS total score. All P < .001 shift from ‘HFEM status to LFEM status’ versus ‘no shift’ and to ‘VLFEM status’ versus ‘no shift’. The between group comparisons for migraine headache days/month (panel a) were done using ANOVA with raw mean changes and standard deviation shown, whereas MSQ (panel b) and MIDAS (panel c) were analyzed using ANCOVA models adjusted for covariates with estimated least squares means and standard errors displayed. Abbreviations: ANOVA, Analysis of Variance; ANCOVA, Analysis of Covariance; BL, baseline; GMB, galcanezumab; HFEM, high-frequency episodic migraine; HFEM, low-frequency episodic migraine; MIDAS, Migraine Disability Index, MSQv2.1 RFR, Migraine-Specific Questionnaire Version 2.1 Role Function Restrictive, VLFEM, very low-frequency episodic migraine